Treating Refractory Hematological Malignancies - Multiple Myeloma (MM): New Treatment Options Driving In-Licensing and M&A

 Treating Refractory Hematological Malignancies - Multiple Myeloma (MM): New
                Treatment Options Driving In-Licensing and M&A

  PR Newswire

  MUMBAI, India, September 23, 2013

MUMBAI, India, September 23, 2013 /PRNewswire/ --

Bharat Book Bureau presents Treating Refractory Hematological Malignancies -
Multiple Myeloma (MM): New Treatment Options Driving In-Licensing and M&A

The report provides an overview of the therapies for Multiple Myeloma (Newly
diagnosed - NDMM and relapsed/ refractory - RRMM), unmet need, and limitations
of the current standard of care (SoC) for relapsed and refractory MM pts. The
report highlights the competition and commercial opportunity in pursuing this
therapy area - Comprehensive list of the early and late stage drugs in the
clinic, their MoA and the companies developing them.

 (Logo: http://photos.prnewswire.com/prnh/20130128/590935 )

Detailed financial and competitive analysis of the companies leading in this
field for this indication - Celgene, Amgen (post-acquisition of Onyx pharma),
and MorphoSys are available within this full report. Key M&A activities that
have taken place in this area in the last 5 years and a list of products in
early /late-stages of development available for in-licensing are highlighted
in the report. This report is built using primary and secondary research data
and in-house proprietary database.

Reasons to buy the report.

Useful for investors, Scientists, Business development managers of Pharma
companies with focus in oncology to address the following-

  *What are the opportunities or new approaches to be deployed in the R&D of
    the company?
  *List of validated and new targets
  *In-licensing opportunities - Is the way to go forward and be in the race?
  *Commercial opportunity and companies' valuation.

KEY POINTS DISCUSSED IN THE REPORT

  *Overview of the Disease and Unmet need
  *Drugs in the pipeline: NDMM & RRMM - Mechanism of Action (MoA) and
    Clinical Stage of development Comparative Clinical data of Late-stage
    Pipelin  e in RRMM and NDDM Ongoing Clinical trial Details of Key Drugs
    in Pipeline
  *Key milestones
  *MPA view on the Future of the drugs in the late-stage pipeline Launch
    Timeline and Commercial Opportunity of Late-stage pipeline M&A and
    Licensing deals in the last 5 years In-licensing and/or M&A Opportunity
  *Detailed Company analysis includes Clinical data of drugs, Milestones, and
    Valuation - Amgen (AMGN), Celgene (CELG), and MorphoSys (MOR)

Table of Contents:

  *Investment Drivers of The Select Companies Covered
  *Multiple Myeloma (MM)
  *Novel Targets including Monoclonal Antibodies And Small Molecules Offer
    In-Licensing Opportunity
  *Ongoing Clinical Trial Details of Key Drugs in the Pipeline
  *Newly Diagnosed Multiple Myeloma (NDMM)
  *Opportunity in Emerging market and Expansion in other Geographies
  *MPA View on the Future of the Drugs in the Late-Stage pipeline
  *Detailed Company Analysis (incl. Clinical Data of Drugs, Milestones, and
    Valuation)
  *Late-stage pipeline
  *Celgene (CELG)
  *Growth from Marketed products and Label expansion
  *Recent Alliances
  *Clinical Data from partnered pipeline products in 2H13 and Beyond
  *Other Partnered programs
  *Novel proprietary technology platforms
  *NPV Valuation

Request for sample pages: 
http://www.bharatbook.com/RequestSample.asp?pid=424897

For more information on the report: 
http://www.bharatbook.com/healthcare-market-research-reports/treating-refractory-hematological-malignancies-multiple-myeloma-mmnew-treatment-options-driving-in-licensing-and-m-a.html
Related Reports:

  *Hematological Tumor - Pipeline Review, H1 2013
  *Treating Refractory Hematological Malignancies - Myelodysplastic Syndromes
    (MDS) and Acute Myeloid Leukemia (AML): Emerging Therapeutics
  *Other Hematological Disorders - Pipeline Review, H1 2013
  *Drugs and Diagnostics for Hematological Disorders: Global Markets

Related Category:

  *Hematological
  *Drugs
  *Treatment

About Bharat Book Bureau

Bharat Book Bureau is the leading market research information aggregator that
provides market research reports, industry analysis, company profiles,
business reports, country reports, newsletters and online databases. Our
clients include Corporate, Consulting firms, and Academic Institutions and
Government departments across the globe. Bharat Book Bureau provides over a
million reports from more than 400 publishers around the globe. The market
research reports we provide, help global companies examine the different
markets before setting up a business or expanding into different countries
across the world. They give a complete perspective on the current market
scenario, trends, segments and future outlook.

Contact us: Poonam Bharat Book Bureau UK: +44 7405 208461USA/Canada -
1-866-279-8368 (Toll free)India: +91-22-27810772, 27810773 Skype - bharatbook
E-mail: poonam@bharatbook.com

Website: http://www.bharatbook.com

Live Chat - http://bit.ly/19m3TU4
 
Press spacebar to pause and continue. Press esc to stop.